Sort   by:  
 Page size 
MetabolomicsMetabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab
The current pandemic emergence of novel coronavirus disease (COVID-19) poses a relevant threat to global health. SARS-CoV-2 infection is characterized by a wide range of clinical manifestations, ranging from absence of symptoms to severe forms that need intensive care treatment. Here, plasma-EDTA sa...
2022-02-21 | MTBLS2336 | MetaboLights
TranscriptomicsCombination of peripheral blood gene expression profiles and clinical parameters predicts response for tocilizumab (anti-IL6) treatment in rheumatoid arthritis
We used microarrays to identify markers predicting responder status in tocilizumab treatment in rheumatoid arthritis in 13 patients at week 0 and week 4 of treatment. Peripheral blood samples were obtained at week 0 and week 4 of tocilizumab treatment and global gene expression profiling identified ...
ORGANISM(S): Homo sapiens 
2011-03-01 | E-GEOD-25160 | biostudies-arrayexpress
ProteomicsShort Term Immune Response to IL6 inhibition (Tocilizumab)
we examined the effects of IL6 inhibition treatment on biologic molecular pathways in a 59 year old patient well diagnosed with RA with inadequate response to DMARD thus treated with tocilizumab. To assess the immunological outcome we used quantitative proteome analysis to evaluate changes in the pr...
ORGANISM(S): Homo sapiens (Human) 
2016-01-05 | PXD002686 | Pride
Tocilizumab Il6 Rheumatoid arthritis 
TranscriptomicsEffects of tocilizumab versus methotrexate therapy on gene expression profiles in the early rheumatoid arthrtis synovium
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we investigated the global molecular effects of Tocilizumab, an approved humanized anti-IL6 Receptor antibody, versu...
ORGANISM(S): Homo sapiens 
2013-12-30 | E-GEOD-45867 | biostudies-arrayexpress
TranscriptomicsGene Expression Analysis in Peripheral Blood of Patients with Rheumatoid Arthritis
Peripheral blood cells in patients with rheumatoid arthritis before/after IL-6 inhibition The obtained conclusions on the change of each gene expression level before and after MRA medication were as follows. (1) In the case of IL-6, the specific time profile that the expression level dropped at day ...
ORGANISM(S): Homo sapiens 
2010-06-24 | E-GEOD-12653 | biostudies-arrayexpress
GenomicsSkin biopsy expression from the faSScinate phase 2 study of tocilizumab in systemic sclerosis
Skin biopsy expression from the faSScinate phase 2 study of tocilizumab in systemic sclerosis
PRJNA1049465 | ENA
GenomicsTranscriptome change after tocilizumab therapy in rheumatoid arthritis patients
Transcriptome change after tocilizumab therapy in rheumatoid arthritis patients
PRJNA450318 | ENA
GenomicsEffect of subcutaneous tocilizumab on gene expression of neutrophils in fibromyalgia patients
Effect of subcutaneous tocilizumab on gene expression of neutrophils in fibromyalgia patients
PRJNA955775 | ENA
GenomicsSingle-cell RNA sequencing of Tocilizumab-treated peripheral blood mononuclear cells as an in vitro model of inflammation
Single-cell RNA sequencing of Tocilizumab-treated peripheral blood mononuclear cells as an in vitro model of inflammation
PRJNA684327 | ENA
TranscriptomicsSingle-cell RNA sequencing of Tocilizumab-treated peripheral blood mononuclear cells as an in vitro model of inflammation
COVID-19 has posed a significant threat to global health. Early data has revealed that IL-6, a key regulatory cytokine, plays an important role in the cytokine storm of COVID-19. Multiple trials are therefore looking at the effects of Tocilizumab, an IL-6 receptor antibody that inhibits IL-6 activit...
ORGANISM(S): Homo sapiens 
2020-12-11 | GSE163014 | GEO
Sort   by:  
 Page size